摘要
To the Editor：The t（9;22）（q34;q 11） （Philadelphia chromosome [Ph]） balanced translocation results in fusion of the BCR gene at 22q11 with cytoplasmic tyrosine kinase gene ABL1 and plays an essential role in leukemic transformation.The Ph is an infrequent finding in de novo acute myeloid leukemia （AML）,approximately 0.5-3% of newly diagnosed patients. The World Health Organization （WHO） recently released a revised version of the Classification of Hematopoietic and Lymphoid Malignancies,a new provisional category of AM L with BCR-ABL1 was added to recognize these rare Ph AML cases that could benefit from tyrosine-kinase inhibitor （TKI） therapy. It is required to enlarge the sample size and research the molecular or genomic features to increase the argument in favor ofPh AML as a real entity.
To the Editor：The t（9;22）（q34;q 11） （Philadelphia chromosome [Ph]） balanced translocation results in fusion of the BCR gene at 22q11 with cytoplasmic tyrosine kinase gene ABL1 and plays an essential role in leukemic transformation.The Ph is an infrequent finding in de novo acute myeloid leukemia （AML）,approximately 0.5-3% of newly diagnosed patients. The World Health Organization （WHO） recently released a revised version of the Classification of Hematopoietic and Lymphoid Malignancies,a new provisional category of AM L with BCR-ABL1 was added to recognize these rare Ph AML cases that could benefit from tyrosine-kinase inhibitor （TKI） therapy. It is required to enlarge the sample size and research the molecular or genomic features to increase the argument in favor ofPh AML as a real entity.
基金
This work was supported by grants from the National Natural Science funds （No. 81500103）, Natural Science Foundation of Jiangsu Province （BK-20151230）, and the high-level medical talents training project （No. 2016CZLJ027）.
